Horizon Europe

ForthcomingBuyer or supplier accessUmbrella CallCall-level profileTopic screening required

Health single-stage 2027/1

European Union / European Commission · Cluster 1 Health

Timing type=opening | stage=Opening | date=2027-02-10 | continuous=false | confirmed=true | estimated=falseVerified 17 Jul 2026Call / topic ID HORIZON-HLTH-2027-01
Call-level screening required

This is a call-level profile. Individual topic conditions, action types, funding rates, consortium rules and restrictions must be screened.

01

Opportunity snapshot

Collection
Horizon Europe
Source / programme
European Union / European Commission · Cluster 1 Health
Status
Forthcoming
Actionability
Buyer or supplier access
Record granularity
Umbrella Call
Verification date
17 Jul 2026
02

What the opportunity supports

This profile covers the Horizon Europe call or topic “Health single-stage 2027/1”. The official targeting includes: Strong clinical/regulatory design, ethics, data protection and public-health relevance needed.

03

Thematic fit

Health research and procurement

Health research and procurement
04

Egypt eligibility and applicant role

Public buyers normally lead the action. Companies are most often technology suppliers or contractors, and only participate as beneficiaries where the topic explicitly permits.

Egyptian participation is subject to the live call, topic conditions, General Annexes and any strategic, security, ownership, control or establishment restrictions.

05

Best-fit applicants

Health consortia: disabilities, climate-health exposome, adaptation, antivirals, antibodies, antimicrobials, child NCDs, ADR, cell-free protein synthesis.

Health consortia: disabilities, climate-health exposome, adaptation, antivirals, antibodies, antimicrobials, child NCDs, ADR, cell-free protein synthesis
06

Funding and instrument

Funding scale
Indicative EUR 3-11m per project
Instrument
RIA generally 100%; IA generally 70% for for-profit entities; PCP grant rate generally 100% for beneficiaries, unless the topic states otherwise.
Scale basis
Indicative
Co-financing
Topic-specific - Funding rate and own contribution vary by action type and topic
IAPCPRIAIAPCPRIA
07

Access and co-financing

Topic-specific - Funding rate and own contribution vary by action type and topic

Buyer or supplier routeBuyer-led / supplier route
08

Submission timing

  1. Openingtype=opening | stage=Opening | date=2027-02-10 | continuous=false | confirmed=true | estimated=false
09

Applicant positioning

Build the consortium around clinical and patient needs, regulatory science, data governance, validation sites and a credible adoption/reimbursement or procurement route.

10

Strategic fit and caveats

Public buyers lead the grant; suppliers generally compete later under procurement rules and cannot assume beneficiary status. This is a call-level profile; individual topic conditions must be screened before application.

Priority
High
Priority rationale
for aligned industrial partners
Verification confidence
High
11

Horizon classification

Programme family
Horizon Europe
Pillar / programme part
Pillar II · Cluster 1 Health
Call / topic ID
HORIZON-HLTH-2027-01
Call year
2027
Action type
RIA|IA|PCP
Record granularity
Umbrella Call
12

Egyptian private-sector role

Public buyers normally lead the action. Companies are most often technology suppliers or contractors, and only participate as beneficiaries where the topic explicitly permits.

Coordination eligibility
Public buyers or eligible procurers lead; companies normally participate as suppliers
Access family
Buyer or supplier route
13

Consortium and beneficiary conditions

Mono-beneficiary status
No
Consortium conditions
RIA standard consortium; PCP requires procurer group
14

Funding and financial burden

Indicative project ticket
Indicative EUR 3-11m per project
Call budget
call budget EUR 341.6m
Expected awards
42
Funding rate
RIA generally 100%; IA generally 70% for for-profit entities; PCP grant rate generally 100% for beneficiaries, unless the topic states otherwise.
Co-financing
Topic-specific - Funding rate and own contribution vary by action type and topic
15

TRL and maturity

TRL range
Not specified
Maturity
Demand-led procurement maturity; requires a defined unmet need and buyer pathway.
16

Restrictions and screening

Strategic restrictions
No special restriction identified at profile level
Security restrictions
No special restriction identified at profile level
Ownership / control restrictions
No special restriction identified at profile level
Establishment restrictions
No special restriction identified at profile level
Screening note
No special restriction identified at profile level; topic conditions, the General Annexes and live portal still control
17

Source and verification

Adopted Horizon Europe 2026-2027 work programme and official programme source; live Funding & Tenders Portal recheck required

ICF Gateway support

Turn screening intelligence into a qualified next step

Assess eligibility, applicant role, consortium needs, co-financing, maturity, evidence gaps and positioning before investing in a proposal.